Pfizer Inc
NYSE:PFE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.5384
31.39
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Pfizer Inc
Pfizer Inc
Revenue
Pfizer Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$60.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
14%
|
CAGR 10-Years
2%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$87.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$47.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
11%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$63.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Revenue
$9.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$40.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
Pfizer Inc
Revenue Breakdown
Breakdown by Geography
Pfizer Inc
|
Total Revenue:
58.5B
USD
|
|
United States:
27.1B
USD
|
|
Emerging Markets:
12B
USD
|
|
Developed Europe:
11.7B
USD
|
|
Developed Rest Of World:
7.8B
USD
|
Breakdown by Segments
Pfizer Inc
|
Total Revenue:
58.5B
USD
|
|
Biopharma:
57.2B
USD
|
|
Comirnaty Direct Sales And Alliance Revenues:
11.2B
USD
|
|
Eliquis Alliance Revenues And Direct Sales:
6.7B
USD
|
|
Prevnar Family:
6.4B
USD
|
|
Ibrance:
4.8B
USD
|
|
Vyndaqel Family:
3.3B
USD
|
|
All Other Specialty Care:
2.2B
USD
|
|
All Other Primary Care:
1.8B
USD
|
|
Xeljanz:
1.7B
USD
|
|
Business Innovation Segment:
1.3B
USD
|
|
Paxlovid:
1.3B
USD
|
|
Pfizer Centreone:
1.3B
USD
|
|
Xtandi Alliance Revenues:
1.2B
USD
|
|
All Other Anti-Infectives:
1.1B
USD
|
|
Inlyta:
1B
USD
|
|
Nurtec Odt/Vydura:
928m
USD
|
|
Abrysvo:
890m
USD
|
|
Enbrel (Outside The United States And Canada):
830m
USD
|
|
Sulperazon:
757m
USD
|
|
Bosulif:
645m
USD
|
|
Ig Portfolio:
584m
USD
|
|
Genotropin:
539m
USD
|
|
Lorbrena:
539m
USD
|
|
Zavicefta:
511m
USD
|
|
Inflectra:
490m
USD
|
|
All Other Oncology:
433m
USD
|
|
Benefix:
424m
USD
|
|
Zirabev:
424m
USD
|
|
Zithromax:
406m
USD
|
|
Premarin Family:
397m
USD
|
|
Ruxience:
390m
USD
|
|
Xalkori:
374m
USD
|
|
Retacrit:
340m
USD
|
|
Medrol:
339m
USD
|
|
Bmp2:
338m
USD
|
|
Oxbryta:
328m
USD
|
|
Aromasin:
301m
USD
|
|
Fsme-Immun/Ticovac:
268m
USD
|
|
Somavert:
267m
USD
|
|
Fragmin:
238m
USD
|
|
Besponsa:
236m
USD
|
|
Refacto Af/Xyntha:
230m
USD
|
|
Braftovi:
213m
USD
|
|
Cresemba:
195m
USD
|
|
Bavencio Alliance Revenues:
190m
USD
|
|
Vfend:
187m
USD
|
|
Sutent:
180m
USD
|
|
Nimenrix:
179m
USD
|
|
Mektovi:
174m
USD
|
|
Bicillin:
158m
USD
|
|
Cibinqo:
128m
USD
|
|
Trumenba:
126m
USD
|
|
Trazimera:
91m
USD
|
|
Padcev:
52m
USD
|
|
Adcetris:
46m
USD
|
|
Pfizer Ignite:
44m
USD
|
|
Tukysa:
17m
USD
|
|
Tivdak:
4m
USD
|
Pfizer Inc
Glance View
Pfizer Inc., a name synonymous with pharmaceutical innovation, embarked on its journey in 1849 when German immigrants Charles Pfizer and Charles Erhart founded the company in Brooklyn, New York. Over the decades, the modest chemical business transformed into a titan of the pharmaceutical industry, delivering breakthroughs that have shaped modern medicine. The company operates through its robust engine of research and development, continually investing billions into discovering and bringing to market medications that address unmet medical needs. Spanning therapeutic areas such as oncology, vaccines, rare diseases, and cardiovascular and metabolic health, Pfizer's strategic focus ensures a diverse product pipeline that aligns with global health trends and challenges. The company's revenue model is predominantly driven by the development, marketing, and sale of its pharmaceutical products. Blockbuster drugs like Lipitor and recently, the COVID-19 vaccine developed in collaboration with BioNTech, have contributed significantly to its earnings. Pfizer's ability to maintain a strong balance between branded pharmaceuticals and generics allows it to effectively cater to both emerging markets and developed economies, while its strategic partnerships and acquisitions further bolster its reach and capabilities. The synergy of science and business acumen at Pfizer has made it not only a hub of medical innovation but also a formidable enterprise in the competitive landscape of healthcare.
See Also
What is Pfizer Inc's Revenue?
Revenue
60.1B
USD
Based on the financial report for Sep 29, 2024, Pfizer Inc's Revenue amounts to 60.1B USD.
What is Pfizer Inc's Revenue growth rate?
Revenue CAGR 10Y
2%
Over the last year, the Revenue growth was -13%. The average annual Revenue growth rates for Pfizer Inc have been -4% over the past three years , 14% over the past five years , and 2% over the past ten years .
You don't have any saved screeners yet
